Poltreg S.A. is a biotechnology company based in Poland that focuses on developing innovative therapies for autoimmune diseases. The company specializes in using T-regulatory cells (TREGs) to develop a new generation of medicines aimed at treating autoimmune diseases , such as diabetes type 1 and multiple sclerosis. Poltreg S.A. is currently conducting various stages of research and development projects in these areas to offer medical solutions to those suffering from autoimmune diseases . The company's strong commitment to research and development is reinforced by its team of qualified scientists and researchers dedicated to developing new technologies and techniques to improve health outcomes.
Year founded2015
Served areaWorldwide
HeadquartersWały Piastowskie 1/Lok.1508, 80-855 Gdańsk – Poland
PLPLTRG00038
LEI259400XSAJTERJ42VZ86
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.